| Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis E Tacconelli, E Carrara, et al. The Lancet Infectious Diseases, 2017 | 5380 | 2017 |
| Challenges of antibacterial discovery LL Silver Clinical microbiology reviews 24 (1), 71-109, 2011 | 1738 | 2011 |
| Platensimycin is a selective FabF inhibitor with potent antibiotic properties J Wang, SM Soisson, K Young, W Shoop, S Kodali, A Galgoci, R Painter, ... Nature 441 (7091), 358-361, 2006 | 1017 | 2006 |
| Outbreak of Klebsiella pneumoniae Producing a New Carbapenem-Hydrolyzing Class A β-Lactamase, KPC-3, in a New York Medical Center N Woodford, PM Tierno Jr, K Young, L Tysall, MFI Palepou, E Ward, ... Antimicrobial agents and chemotherapy 48 (12), 4793-4799, 2004 | 656 | 2004 |
| Antibacterial agents that inhibit lipid A biosynthesis HR Onishi, BA Pelak, LS Gerckens, LL Silver, FM Kahan, MH Chen, ... Science 274 (5289), 980-982, 1996 | 512 | 1996 |
| Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala M Ge, Z Chen, H Russell, J Kohler, LL Silver, R Kerns, S Fukuzawa, ... Science 284 (5413), 507-511, 1999 | 448 | 1999 |
| Discovery and development of new antibiotics: the problem of antibiotic resistance. LL Silver, KA Bostian Antimicrobial agents and chemotherapy 37 (3), 377, 1993 | 405 | 1993 |
| Multi-targeting by monotherapeutic antibacterials LL Silver Nature Reviews Drug Discovery 6 (1), 41-55, 2007 | 389 | 2007 |
| Fosfomycin: mechanism and resistance LL Silver Cold Spring Harbor perspectives in medicine 7 (2), a025262, 2017 | 323 | 2017 |
| Discovery of FabH/FabF inhibitors from natural products K Young, H Jayasuriya, JG Ondeyka, K Herath, C Zhang, S Kodali, ... Antimicrobial agents and chemotherapy 50 (2), 519-526, 2006 | 261 | 2006 |
| What is an “ideal” antibiotic? Discovery challenges and path forward SB Singh, K Young, LL Silver Biochemical pharmacology 133, 63-73, 2017 | 256 | 2017 |
| Analysis of the clinical antibacterial and antituberculosis pipeline U Theuretzbacher, S Gottwalt, P Beyer, M Butler, L Czaplewski, ... The Lancet Infectious Diseases 19 (2), e40-e50, 2019 | 241 | 2019 |
| Bacteriophage T4 gene 41 protein, required for the synthesis of RNA primers, is also a DNA helicase. M Venkatesan, LL Silver, NG Nossal Journal of Biological Chemistry 257 (20), 12426-12434, 1982 | 238 | 1982 |
| The envA permeability/cell division gene of Escherichia coli encodes the second enzyme of lipid A biosynthesis K Young, LL Silver, D Bramhill, P Cameron, SS Eveland, CRH Raetz, ... Journal of Biological Chemistry 270 (51), 30384-30391, 1995 | 227 | 1995 |
| A Gestalt approach to Gram-negative entry LL Silver Bioorganic & medicinal chemistry 24 (24), 6379-6389, 2016 | 187 | 2016 |
| Analysis of the clinical pipeline of treatments for drug-resistant bacterial infections: despite progress, more action is needed MS Butler, V Gigante, H Sati, S Paulin, L Al-Sulaiman, JH Rex, ... Antimicrobial agents and chemotherapy 66 (3), e01991-21, 2022 | 167 | 2022 |
| Determination of selectivity and efficacy of fatty acid synthesis inhibitors S Kodali, A Galgoci, K Young, R Painter, LL Silver, KB Herath, SB Singh, ... Journal of Biological Chemistry 280 (2), 1669-1677, 2005 | 160 | 2005 |
| Novel inhibitors of bacterial cell wall synthesis LL Silver Current opinion in microbiology 6 (5), 431-438, 2003 | 150 | 2003 |
| Screening of natural products for antimicrobial agents L Silver, K Bostian European Journal of Clinical Microbiology & Infectious Diseases 9 (7), 455-461, 1990 | 141 | 1990 |
| Does the cell wall of bacteria remain a viable source of targets for novel antibiotics? LL Silver Biochemical pharmacology 71 (7), 996-1005, 2006 | 138 | 2006 |
